A New Window Into Parkinson’s Disease? Mabwell Advances Alpha-Synuclein Imaging

Diagnosing Parkinson’s disease early is still more art than science.  Symptoms come late. Imaging is indirect. Certainty is rare. That’s what makes this development from Mabwell worth watching.

Its investigational imaging agent—18F-FD4 (SST001), has just been cleared by China’s regulator to enter Phase I clinical trials.

What’s New: A First Step Toward Direct Disease Visualization?

The approval comes from China’s regulator (NMPA) and allows SST001 to move into human testing. The trial will be conducted at:

• Huashan Hospital, Fudan University
• Affiliated Hospital of Jiangnan University

Study design:

• Open-label, non-randomized
• Includes:
  • Healthy volunteers
  • Parkinson’s disease (PD) patients
  • Multiple system atrophy (MSA) patients

Primary focus:

• Safety and tolerability
• Biodistribution
• Radiation dosimetry
• Pharmacokinetics

In other words: Does it work safely inside the human body?

The Science: Targeting Alpha-Synuclein

At the core of this innovation is a protein: alpha-synuclein (α-syn). Why it matters:

• Misfolded α-syn accumulates in the brain
• Drives diseases like:
  • Parkinson’s disease (PD)
  • Multiple system atrophy (MSA)

But here’s the gap:

Today, clinicians can’t directly visualize α-syn in living patients. SST001 aims to change that.

What SST001 Actually Does?

SST001 is a PET tracer. That means:

• It binds specifically to α-syn aggregates
• Enables real-time brain imaging
• Provides quantitative data, not just indirect signals

Potential use cases:

• Earlier and more accurate diagnosis
• Differentiating PD vs MSA
• Selecting patients for clinical trials
• Monitoring treatment response

This shifts diagnosis from: Symptom-based → biology-based

Why This Matters: A Massive and Growing Burden?

The scale of Parkinson’s disease is hard to ignore:

• 11.8 million patients globally (2021)
• China alone accounts for 40%+

Growth drivers:

• Aging population
• Improved diagnosis rates

Meanwhile, MSA:

• Rare but aggressive
• Median survival: 6–10 years

Both lack precise diagnostic tools.

Not Just China: A Global Development Play

This isn’t a local program. SST001 is advancing globally.

• Received Research IND clearance from the U.S. FDA
• First patient already dosed in the U.S.
• Backed by a $3.84M grant from The Michael J. Fox Foundation for Parkinson's Research

That combination—China + U.S. clinical progress—matters.

It increases:

• Regulatory credibility
• Data robustness
• Global commercialization potential

The Ecosystem Behind It

SST001 is developed by SynuSight Biotech, an incubated company of Mabwell. Their focus:

• Protein misfolding biology
• Targets like:
  • Alpha-synuclein
  • Tau
  • Amyloid-beta

With advanced tools like:

• Cryo-EM
• In-cell NMR
• Filament imaging

This is deep structural biology—not surface-level innovation.

Let’s Pressure-Test This (Devil’s Protocol)

The promise is compelling. But there are real challenges.

1. Signal Specificity

• Can SST001 distinguish α-syn from other protein aggregates reliably?

2. Clinical Utility vs Complexity

• Even if imaging works, will it:
  • Change treatment decisions?
  • Or remain a research tool?

3. Competition Landscape

• Tau and amyloid imaging already exist
• α-syn imaging has been historically difficult

If solved, it’s a breakthrough. If not, it stalls like past attempts.

4. Cost and Accessibility

• PET imaging is expensive
• Will this scale beyond major centers?

Where This Could Win Big?

If SST001 works as intended, it unlocks three major advantages:

1. Earlier Diagnosis

Detect disease before major symptom onset.

2. Better Clinical Trials

Select the right patients with confirmed biology.

3. Drug Development Acceleration

Enable target engagement validation for new therapies.

Final Take

Mabwell isn’t just developing another diagnostic tool. It’s attempting something the field has struggled with for years:

Direct, real-time visualization of alpha-synuclein in the human brain

If successful, SST001 could become:

• A diagnostic standard
• A clinical trial enabler
• A cornerstone for future neurodegenerative therapies

But like all imaging breakthroughs, the real test isn’t technical success. It’s whether clinicians actually change decisions because of it.